The Drug Triad That Could Overwhelm Plans

From One, to Some, to Many: Gene Therapies, Cancer Drugs, Diabetes Drugs, The Drug Triad That Could Overwhelm Plans  

 
Reformulary Group CEO and former Ontario ‘drug czar’ Helen Stevenson joins CPBI to talk about new and existing therapies that could overwhelm employer benefit plans – gene therapies, cancer drugs and diabetes treatment. Would it surprise you to know that a gene therapy costing more than $2.8 million per patient has recently been approved in Canada, or that some private plans are paying claims for cancer drugs that are typically covered by cancer agencies? As more and more expensive drugs roar up the regulatory pipeline, understanding their cost and how plans can be informed and manage their impact has never been more important.

SPEAKER  

THANK YOU TO OUR SPONSORS